Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.85

-4.4%

2:39 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (149)	4/11/1999 2:49:00 PM
From: LLCF	Read Replies (1) of 52153

<They do have an anti-angiogenesis candidate> Front page Chicago Tribune, main article... pictures, the whole shot, about Folkman, angio/endo statin. Nothing new, just what has happened up till now. Trials to start this year (forth quarter) at Wisconsin-Madison, and in Texas. Northwestern Dr. Gerald Soff believes he has found a more efficient method of producing angiostatin. Mentions that the 2 trials are Entremed trials. Mostly a "Folkman piece". DAK

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next